Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

5.01
+0.09001.83%
Post-market: 4.94-0.0700-1.40%18:21 EDT
Volume:209.38K
Turnover:1.01M
Market Cap:108.70M
PE:-1.56
High:5.02
Open:4.87
Low:4.54
Close:4.92
52wk High:17.94
52wk Low:3.35
Shares:21.70M
Float Shares:11.17M
Volume Ratio:1.54
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2080
EPS(LYR):-0.7400
ROE:-66.02%
ROA:-40.38%
PB:1.45
PE(LYR):-6.77

Loading ...

Aardvark Therapeutics Establishes $150 Million Equity Program

TIPRANKS
·
Mar 24

Aardvark Therapeutics Inc - Enters Equity Distribution Agreement With Piper Sandler on March 23, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 24

Aardvark Therapeutics Inc - May Offer Shares up to $150 Mln Aggregate Offering Price - SEC Filing

THOMSON REUTERS
·
Mar 24

Aardvark Therapeutics signs equity distribution agreement for up to USD 150 million offering

Reuters
·
Mar 24

Aardvark pauses two obesity drug trials as it reviews side effects

Reuters
·
Mar 24

Aardvark Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live
·
Mar 24

Aardvark Therapeutics files $400M mixed securities shelf

TIPRANKS
·
Mar 24

Aardvark files USD 400 million shelf registration for common stock and debt securities

Reuters
·
Mar 24

Aardvark Therapeutics Inc - May Offer up to $400 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Mar 24

Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)

TIPRANKS
·
Mar 24

Aardvark Therapeutics reports lower-than-expected 2025 net loss

Reuters
·
Mar 24

Aardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million

Reuters
·
Mar 24

Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate

Benzinga Earnings
·
Mar 24

Aardvark Therapeutics: Pauses Ard-201 Obesity Program Including Power and Strength Trials; Further Guidance Expected Q2 2026

THOMSON REUTERS
·
Mar 24

Aardvark Therapeutics: Pauses Phase 3 Hero and Ole Trials for Ard-101 in Pws; Further Guidance Expected Q2 2026

THOMSON REUTERS
·
Mar 24

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
Mar 24